The results of the present and previous studies [3, 29, 30] suggest that SG and other Trop2 ADCs may represent a novel treatment option, including patients with p16-negative cervical adenocarcinomas, and should be explored in clinical trials. Here, TACSTD2 is linked to cervical adenocarcinoma.